Erpenbeck VJ, Vets E, Gheyle L, Osuntokun W, Larbig M, Neelakantham S, Sandham D, Dubois G, Elbast W, Goldsmith P, Weiss M. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers. Clin Pharmacol Drug Dev. 2016 Jul;5(4):306-13 Explanation of the corrections: The purity/drug content of the reference standard for the acyl glucuronide metabolite was previously overestimated. Consequently, a correction factor of 0.76 was applied to revise these concentrations. These changes do not affect the conclusions or any other findings of the manuscript.
展开▼
